Left Ventricular Post-Infarct Remodeling: Implications for Systolic Function Improvement and Outcomes in the Modern

Pieter van der Bijl1, Rachid Abou1, Laurien Goedemans1

  • 1Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Leiden, the Netherlands.

JACC. Heart Failure
|December 16, 2019
PubMed

Insights

Left ventricular remodeling after heart attacks is common with modern treatments. While it doesn't affect long-term survival, it significantly increases heart failure hospitalizations, necessitating improved preventative strategies.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Clinical Medicine

Background:

  • Left ventricular (LV) remodeling post-ST-segment elevation myocardial infarction (STEMI) is linked to adverse outcomes.
  • Previous studies on LV remodeling prognoses were conducted before current primary percutaneous coronary intervention (PCI) and optimal pharmacotherapy standards.
  • Re-evaluation of LV remodeling's long-term impact in the contemporary STEMI treatment era is crucial.

Purpose of the Study:

  • To investigate the impact of post-infarct left ventricular (LV) remodeling on patient outcomes in the current era of STEMI management.
  • To assess the prognostic significance of LV remodeling following primary PCI for STEMI.

Main Methods:

  • Analysis of echocardiograms from 1,995 STEMI patients treated with primary PCI at baseline and up to 12 months.
  • LV remodeling defined as a ≥20% increase in LV end-diastolic volume at 3, 6, or 12 months post-infarct.
  • Outcomes, including mortality and heart failure hospitalization, were analyzed over a median follow-up of 94 months.

Main Results:

  • Nearly half (48%) of STEMI patients exhibited LV remodeling within 12 months.
  • No significant difference in long-term survival was observed between patients with and without LV remodeling (p=0.144).
  • LV remodelers had a significantly higher likelihood of hospitalization for heart failure compared to non-remodelers (p<0.001).

Conclusions:

  • Post-STEMI LV remodeling is prevalent even with contemporary primary PCI and pharmacotherapy.
  • LV remodeling does not impact long-term mortality but is associated with increased heart failure hospitalizations.
  • Intensified preventative strategies are needed for STEMI patients who develop LV remodeling.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
615
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
274
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
321
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
319
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
344